Nephrocare Health Services (NEPHROPLUS) Q4 23/24 earnings summary

Executive summary

• FY24 consolidated revenue rose to ₹5,661.55 million from ₹4,372.95 million; net profit was ₹351.33 million versus a ₹117.89 million loss.

• Standalone revenue was ₹4,440.34 million versus ₹3,912.02 million, with net profit of ₹38.82 million versus a ₹154.65 million loss.

• Expansion continued through acquisitions in the Philippines; management is considering further expansion of operations.

Financial highlights

• Consolidated revenue from operations ₹5,661.55 million, up from ₹4,372.95 million; other income ₹85.67 million versus ₹59.64 million.

• Consolidated expenses ₹5,415.61 million versus ₹4,518.50 million; profit before tax ₹331.61 million versus a loss of ₹85.91 million.

• Consolidated profit after tax ₹351.33 million versus a loss of ₹117.89 million; total comprehensive income ₹226.56 million versus a loss of ₹84.72 million.

• Consolidated operating cash flow was ₹606.33 million versus ₹112.69 million; year-end cash and cash equivalents were ₹611.51 million versus ₹140.60 million.

Outlook and guidance

• Management reported turnover of ₹4,362.30 million, up from ₹3,861.11 million, and is considering expanding operations beyond the existing level to improve performance.